Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

341. The risk of acute renal failure in patients with chronic kidney disease Full Text available with Trip Pro

The risk of acute renal failure in patients with chronic kidney disease Few studies have defined how the risk of hospital-acquired acute renal failure varies with the level of estimated glomerular filtration rate (GFR). It is also not clear whether common factors such as diabetes mellitus, hypertension and proteinuria increase the risk of nosocomial acute renal failure independent of GFR. To determine this we compared 1,746 hospitalized adult members of Kaiser Permanente Northern California who (...) . Pre-admission baseline diabetes mellitus, diagnosed hypertension and known proteinuria were also independent risk factors for acute kidney failure. Our study shows that the propensity to develop in-hospital acute kidney failure is another complication of chronic kidney disease whose risk markedly increases even in the upper half of stage 3 estimated GFR. Several common risk factors for chronic kidney disease also increase the peril of nosocomial acute kidney failure.

2008 EvidenceUpdates

342. Inflammation and cardiovascular events in individuals with and without chronic kidney disease Full Text available with Trip Pro

Inflammation and cardiovascular events in individuals with and without chronic kidney disease Inflammation and chronic kidney disease predict cardiovascular events. Here we evaluated markers of inflammation including fibrinogen, albumin and white blood cell count in individuals with and without stages 3-4 chronic kidney disease to assess inflammation as a risk factor for adverse events, the synergy between inflammation and chronic kidney disease, and the prognostic ability of these inflammatory (...) markers relative to that of C-reactive protein. Using Atherosclerosis Risk in Communities and Cardiovascular Health Study data, inflammation was defined by worst quartile of at least 2 of these 3 markers. In Cox regression models, inflammation was assessed as a risk factor for a composite of cardiac events, stroke and mortality as well as components of this composite. Among 20 413 patients, inflammation was identified in 3594 and chronic kidney disease in 1649. In multivariable analyses, both

2008 EvidenceUpdates

343. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease Full Text available with Trip Pro

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease Chronic kidney disease (CKD) increases cardiovascular risk and mortality. However, traditional cardiovascular risk factors do not adequately account for the substantial increase in mortality observed in CKD. The aim of this study was to examine the relative contributions of novel cardiovascular risk factors to the risk between CKD and mortality. The study (...) population included 4,680 consecutive new patients from a tertiary care preventive cardiology program from 1996 to 2005. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease (MDRD) method. Baseline levels of traditional (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hypertension, triglycerides, total cholesterol, and fasting glucose) and emerging (apolipoproteins A-I and B, lipoprotein[a], fibrinogen, homocysteine, and high

2008 EvidenceUpdates

344. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. (Abstract)

All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Both end-stage renal disease and chronic kidney disease are increasing worldwide; however, the full effect of chronic kidney disease is unknown because mortality risks for all five stages are unavailable. We assessed prevalence and mortality risks for all stages of chronic kidney disease and quantified its attributable mortality in Taiwan.The cohort consisted of 462 293 (...) and for low socioeconomic status.The national prevalence of chronic kidney disease was 11.93% (95% CI 11.66-12.28), but only 3.54% (3.37-3.68) of participants in the cohort were aware of their disorder. Prevalence was substantially higher in the group with low socioeconomic status than in the high status group (19.87% [19.84-19.91] vs 7.33% [7.31-7.35]). 56 977 (12%) of cohort participants had chronic kidney disease; those with disease had 83% higher mortality for all cause (HR 1.83 [1.73-1.93]) and 100

2008 Lancet

345. The combination of smoking and heavy drinking increased the risk of chronic kidney disease

The combination of smoking and heavy drinking increased the risk of chronic kidney disease The combination of smoking and heavy drinking increased the risk of chronic kidney disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The combination of smoking and heavy drinking increased the risk of chronic kidney disease Article Text Causation The combination of smoking and heavy drinking increased the risk of chronic kidney disease Statistics

2008 Evidence-Based Nursing

346. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial Full Text available with Trip Pro

C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial This study examined the efficacy of C.E.R.A., a continuous erythropoietin receptor activator, for correcting anemia in patients who had chronic kidney disease (CKD) and were not on dialysis.In this open-label, randomized, parallel-group, Phase III study, 324 adult patients with CKD not on dialysis nor receiving treatment with erythropoiesis-stimulating agents (ESAs) were

2008 EvidenceUpdates Controlled trial quality: uncertain

347. Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease

Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

348. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation

Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B CRD summary This review concluded that treatment with erythropoiesis-stimulating agents (...) for anaemia from chronic kidney disease in adult patients was likely to be optimal when a haemoglobin target of 110g/L was adopted. This conclusion reflects the results of a well-conducted review and appears to be reliable. Authors' objectives To assess the clinical efficacy and safety, and the economic implications of erythropoiesis-stimulating agents for anaemia from chronic kidney disease in adult patients. Searching MEDLINE (from 1966), EMBASE (from 1988) and all EBM reviews were searched

2008 DARE.

349. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation

Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Tonelli M, Klarenbach S, Wiebe N, Shrive F, Hemmelgarn B, Manns B. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Technology Report No 106. 2008 Authors' objectives "The aim of this review was to assess the evidence for clinical efficacy and harms

2008 Health Technology Assessment (HTA) Database.

350. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

351. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease

Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia: summary of trials of cancer, HIV/AIDS, and chronic kidney disease Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

352. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials

Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

353. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis

Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandara N, Hathiwala S, Smith E CRD (...) summary The authors concluded that among patients with chronic kidney disease from any cause, renin angiotensin system blockade reduced myocardial infarctions, heart failure and overall cardiovascular adverse events compared with placebo. The conclusions may need to be interpreted cautiously due to the small number of studies included in the main analyses, unexplained heterogeneity and inconsistent findings across different clinical outcomes. Authors' objectives To determine the effects of renin

2008 DARE.

354. Review: a low protein diet delays end stage renal disease or death in chronic kidney disease

Review: a low protein diet delays end stage renal disease or death in chronic kidney disease Review: a low protein diet delays end stage renal disease or death in chronic kidney disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: a low protein diet delays end stage renal disease or death in chronic kidney disease Article Text Treatment Review: a low protein diet delays end stage renal disease or death in chronic kidney disease

2008 Evidence-Based Nursing

355. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Full Text available with Trip Pro

Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Cilnidipine, a dual L-/N-type calcium channel blocker, dilates both efferent and afferent arterioles and is renoprotective. Our multi-center, open-labeled, and randomized trial compared the antiproteinuric effect of cilnidipine with that of amlodipine in hypertensive patients with kidney disease. A group of 339 patients, already receiving

2008 EvidenceUpdates Controlled trial quality: uncertain

356. Prevalence of chronic kidney disease in the United States. Full Text available with Trip Pro

1988-1994 and NHANES 1999-2004), a nationally representative sample of noninstitutionalized adults aged 20 years or older in 1988-1994 (n = 15,488) and 1999-2004 (n = 13,233).Chronic kidney disease prevalence was determined based on persistent albuminuria and decreased estimated glomerular filtration rate (GFR). Persistence of microalbuminuria (>30 mg/g) was estimated from repeat visit data in NHANES 1988-1994. The GFR was estimated using the abbreviated Modification of Diet in Renal Disease Study (...) Prevalence of chronic kidney disease in the United States. The prevalence and incidence of kidney failure treated by dialysis and transplantation in the United States have increased from 1988 to 2004. Whether there have been changes in the prevalence of earlier stages of chronic kidney disease (CKD) during this period is uncertain.To update the estimated prevalence of CKD in the United States.Cross-sectional analysis of the most recent National Health and Nutrition Examination Surveys (NHANES

2007 JAMA

357. 71% of patients with newly diagnosed chronic kidney disease progressed to renal replacement therapy or death within 3 years

71% of patients with newly diagnosed chronic kidney disease progressed to renal replacement therapy or death within 3 years 71% of patients with newly diagnosed chronic kidney disease progressed to renal replacement therapy or death within 3 years | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here 71% of patients with newly diagnosed chronic kidney disease progressed to renal replacement therapy or death within 3 years Article Text

2007 Evidence-Based Medicine

358. A pre-dialysis psychoeducational intervention increased length of survival more than usual care in patients with chronic kidney disease Full Text available with Trip Pro

A pre-dialysis psychoeducational intervention increased length of survival more than usual care in patients with chronic kidney disease A pre-dialysis psychoeducational intervention increased length of survival more than usual care in patients with chronic kidney disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) kidney disease Article Text Treatment A pre-dialysis psychoeducational intervention increased length of survival more than usual care in patients with chronic kidney disease Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information

2007 Evidence-Based Nursing

359. Statin use and hospitalization for sepsis in patients with chronic kidney disease. Full Text available with Trip Pro

Statin use and hospitalization for sepsis in patients with chronic kidney disease. Patients with chronic kidney disease are at high risk for sepsis and sepsis-related mortality.To assess whether statin use is associated with a reduction in sepsis events [corrected] in dialysis patients.National prospective cohort study that enrolled 1041 incident dialysis patients at 81 US not-for-profit outpatient dialysis clinics from October 1995 to June 1998, with follow-up to January 2005. Statin use (...) adjustment for comorbidities and laboratory values continued to show this protective association (incidence rate ratio, 0.38; 95% CI, 0.21-0.67). In the propensity-matched subcohort, statin use was even more protective (incidence rate ratio, 0.24; 95% CI, 0.11-0.49).Use of statins was strongly and independently associated with a reduction in the risk of sepsis events [corrected] in patients who had chronic kidney disease and were receiving dialysis. Randomized trials of statins in patients with chronic

2007 JAMA

360. Correction of chronic metabolic acidosis for chronic kidney disease patients. Full Text available with Trip Pro

Correction of chronic metabolic acidosis for chronic kidney disease patients. Metabolic acidosis is a feature of chronic kidney disease (CKD) due to the reduced capacity of the kidney to synthesise ammonia and excrete hydrogen ions. It has adverse consequences on protein and muscle metabolism, bone turnover and the development of renal osteodystrophy. Metabolic acidosis may be corrected by oral bicarbonate supplementation or in dialysis patients by increasing the bicarbonate concentration (...) in dialysate fluid.To examine the benefits and harms of treating metabolic acidosis in patients with CKD, both prior to reaching end-stage renal disease (ESRD) or whilst on renal replacement therapy (RRT), with sodium bicarbonate or increasing the bicarbonate concentration of dialysate.We searched CENTRAL (The Cochrane Library, issue 4 2005), Cochrane Renal Group's specialised register (October 2005), MEDLINE (1966 - October 2005) and EMBASE (1980 - October 2005).Randomised controlled trials (RCTs

2007 Cochrane